Similar outcome of upfront‐unrelated and matched sibling stem cell transplantation in idiopathic paediatric aplastic anaemia. A study on behalf of the <scp>UK</scp> Paediatric <scp>BMT</scp> Working Party, Paediatric Diseases Working Party and Severe Aplastic Anaemia Working Party of <scp>EBMT</scp>
-
- Carlo Dufour
- Clinical and Experimental Haematology Unit Giannina Gaslini Children's Hospital Genova Italy
-
- Paul Veys
- Department of Haematology & Bone Marrow Transplantation Great Ormond Street Hospital for Children NHS Foundation Trust London UK
-
- Elisa Carraro
- Paediatric Haematology and Oncology University of Padova Padova Italy
-
- Neha Bhatnagar
- Department of Haematology & Bone Marrow Transplantation Great Ormond Street Hospital for Children NHS Foundation Trust London UK
-
- Marta Pillon
- Paediatric Haematology and Oncology University of Padova Padova Italy
-
- Rob Wynn
- Blood and Marrow Transplant Unit Royal Manchester Children's Hospital Manchester UK
-
- Brenda Gibson
- Department of Paediatric Haematology & Oncology Royal Hospital for Sick Children Glasgow UK
-
- Ajay J. Vora
- Department of Paediatric Haematology The Children's Hospital Sheffield UK
-
- Colin G. Steward
- BMT Unit Royal Hospital for Children Bristol UK
-
- Anna M. Ewins
- Department of Paediatric Haematology & Oncology Royal Hospital for Sick Children Glasgow UK
-
- Rachael E. Hough
- University College Hospital London UK
-
- Josu de la Fuente
- Division of Paediatrics Imperial College Healthcare NHS Trust London UK
-
- Mark Velangi
- Birmingham Children's Hospital Birmingham UK
-
- Persis J. Amrolia
- Department of Haematology & Bone Marrow Transplantation Great Ormond Street Hospital for Children NHS Foundation Trust London UK
-
- Roderick Skinner
- Department of Paediatric and Adolescent Haematology/Oncology and BMT Great North Children's Hospital & Northern Institute for Cancer Research Newcastle upon Tyne UK
-
- Andrea Bacigalupo
- Haematology and Oncology Department IRCCS A.O.U. San Martino Hospital IST Genoa Italy
-
- Antonio M. Risitano
- Haematology Federico II Naples Italy
-
- Gerard Socie
- Hôpital Saint‐Louis Paris France
-
- Regis Peffault de Latour
- Hôpital Saint‐Louis Paris France
-
- Jakob Passweg
- Stem Cell Transplant Team Division of Haematology University Hospital Basel Basel Switzerland
-
- Alicia Rovo
- Haematology University Hospital of Basel Basel Switzerland
-
- André Tichelli
- Haematology University Hospital of Basel Basel Switzerland
-
- Hubert Schrezenmeier
- Institute for Clinical Transfusion Medicine and Immunogenetics Ulm German Red Cross Transfusion Service Baden‐Württemberg‐Hessen und University Hospital Ulm Ulm Germany
-
- Britta Hochsmann
- Institute for Clinical Transfusion Medicine and Immunogenetics Ulm German Red Cross Transfusion Service Baden‐Württemberg‐Hessen und University Hospital Ulm Ulm Germany
-
- Peter Bader
- Division for Stem Cell Transplantation and Immunology Hospital for Children and Adolescents University Hospital Frankfurt Goethe University Frankfurt am Main Germany
-
- Anja van Biezen
- EBMT Data Office University Medical Centre Leiden The Netherlands
-
- Mahmoud D. Aljurf
- Adult Haematology/HSCT Oncology Centre King Faisal Specialist Hospital and Research Centre Riyadh Saudi Arabia
-
- Austin Kulasekararaj
- Department of Haematological Medicine King's College Hospital NHS Foundation Trust London UK
-
- Judith C. Marsh
- Department of Haematological Medicine King's College Hospital NHS Foundation Trust London UK
-
- Sujith Samarasinghe
- Department of Haematology & Bone Marrow Transplantation Great Ormond Street Hospital for Children NHS Foundation Trust London UK
抄録
<jats:title>Summary</jats:title><jats:p>We explored the feasibility of unrelated donor haematopoietic stem cell transplant (HSCT) upfront without prior immunosuppressive therapy (IST) in paediatric idiopathic severe aplastic anaemia (SAA). This cohort was then compared to matched historical controls who had undergone first‐line therapy with a matched sibling/family donor (MSD) HSCT (<jats:italic>n</jats:italic> = 87) or IST with horse antithymocyte globulin and ciclosporin (<jats:italic>n</jats:italic> = 58) or second‐line therapy with unrelated donor HSCT post‐failed IST (<jats:italic>n</jats:italic> = 24). The 2‐year overall survival in the upfront cohort was 96 ± 4% compared to 91 ± 3% in the MSD controls (<jats:italic>P</jats:italic> = 0·30) and 94 ± 3% in the IST controls (<jats:italic>P</jats:italic> = 0·68) and 74 ± 9% in the unrelated donor HSCT post‐IST failure controls (<jats:italic>P</jats:italic> = 0·02).The 2‐year event‐free survival in the upfront cohort was 92 ± 5% compared to 87 ± 4% in MSD controls (<jats:italic>P</jats:italic> = 0·37), 40 ± 7% in IST controls (<jats:italic>P</jats:italic> = 0·0001) and 74 ± 9% in the unrelated donor HSCT post‐IST failure controls (<jats:italic>n</jats:italic> = 24) (<jats:italic>P</jats:italic> = 0·02). Outcomes for upfront‐unrelated donor HSCT in paediatric idiopathic SAA were similar to MSD HSCT and superior to IST and unrelated donor HSCT post‐IST failure. Front‐line therapy with matched unrelated donor HSCT is a novel treatment approach and could be considered as first‐line therapy in selected paediatric patients who lack a MSD.</jats:p>
収録刊行物
-
- British Journal of Haematology
-
British Journal of Haematology 171 (4), 585-594, 2015-07-28
Wiley